

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/86, 7/01, 7/04, C07K 14/145, 14/16, A61K 48/00, 39/21</b>		A1	(11) International Publication Number: <b>WO 98/51810</b>
			(43) International Publication Date: 19 November 1998 (19.11.98)
(21) International Application-Number: <b>PCT/US98/10144</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: <b>12 May 1998 (12.05.98)</b>			
(30) Priority Data: <b>60/046,891 13 May 1997 (13.05.97) US</b>			
(71) Applicant (for all designated States except US): <b>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL [US/US]; 308 Bynum Hall, CB #4105, Chapel Hill, NC 27599-4105 (US).</b>			
(72) Inventor; and		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(75) Inventor/Applicant (for US only): <b>OLSEN, John, C. [US/US]; 127 Justice Street, Chapel Hill, NC 27516 (US).</b>			
(74) Agents: <b>BISWAS, Sorojini, J. et al.; Myers, Bigel, Sibley &amp; Sajovec, P.A., P.O. Box 37428, Raleigh, NC 27627 (US).</b>			

(54) Title: **LENTIVIRUS-BASED GENE TRANSFER VECTORS**

(57) Abstract

A recombinant lentiviral vector expression system comprises a first vector that comprises a nucleic acid sequence of at least part of the Equine Infectious Anemia Virus (EIAV) genome. The vector contains at least one defect in at least one gene encoding the EIAV structural protein, but is preferably a *gag/pol* expression vector. The expression system further comprises a second vector, also comprising a nucleic acid sequence of at least part of the Equine Infectious Anemia Virus (EIAV) genome, and additionally containing a multiple cloning site wherein a heterologous gene may be inserted. The expression system also comprises a third vector which expresses a viral envelope protein. The first and third vector are packaging signal-defective. When the expression system is transfected into a lentivirus-permissive cell, replication-defective EIAV particles may be produced, which particles are useful in delivering heterologous genes to a broad range of both dividing and non-dividing cells.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## LENTIVIRUS-BASED GENE TRANSFER VECTORS

### RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application Serial No. 60/046,891, filed May 13, 1997, which application is incorporated herein in its entirety.

### FIELD OF THE INVENTION

This invention relates to viruses as vectors useful in gene delivery, and more specifically to lentiviral vectors useful in gene delivery to non-dividing and dividing cells.

### BACKGROUND OF THE INVENTION

The capacities to introduce a particular foreign or native gene sequence into a mammalian cell and to control the expression of that gene are of substantial value in the fields of medical and biological research. Such capacities provide a means for studying gene regulation, and for designing a therapeutic basis for the treatment of disease.

The introduction of a particular foreign or native gene into a mammalian host cell is facilitated by introducing a gene sequence into a suitable nucleic acid vector. A variety of methods have been developed which are capable of permitting the introduction of such a recombinant vector into a desired host cell. In contrast to methods which involve DNA transformation or transfection, the use of viral vectors can result in the rapid introduction of the recombinant molecule in a wide variety of host cells. In particular, viral vectors have been employed in order to increase the efficiency of introducing a recombinant nucleic acid vector into host cells. Viruses that have been employed as vectors for the transduction and expression of exogenous genes in mammalian cells include SV40 virus (*see, e.g.,* H. Okayama et al., *Molec. Cell. Biol.* 5, 1136-1142 (1985)); bovine papilloma virus (*see, e.g.,* D. DiMaio et al., *Proc. Natl. Acad. Sci. USA* 79, 4030-4034 (1982)); adenovirus (*see, e.g.,* J.E. Morin et al., *Proc. Natl. Acad. Sci. USA* 84, 4626 (1987)), adeno-associated virus (AAV; *see, e.g.,* N. Muzyczka et al., *J. Clin. Invest.* 94, 1351 (1994)); herpes simplex virus (*see, e.g.,* A.I. Geller, et al., *Science* 241, 1667 (1988)), and others.

Retrovirus-based vectors are particularly favored as tools to achieve stable, integrated gene transfer of foreign genes into mammalian cells. Retroviruses that have been employed as vectors for the introduction and expression of exogenous genes in mammalian cells include the Moloney murine sarcoma virus (T. Curran et al., *J. Virol.* 44, 674-682 (1982); A. Gazit et al, *J. Virol.* 60, 19-28 (1986)) and murine leukemia viruses (MuLV; A.D. Miller, *Curr. Top. Microbiol. Immunol.* 158, 1-24 (1992).

Efforts to introduce recombinant molecules into mammalian cells have been hampered by the inability of many cells to be infected by the above-described viral or retroviral vectors. Limitations on retroviral vectors, for example, include a relatively restricted host range, based in part on the level of expression of the membrane protein that serves as the viral receptor. M.P. Kavanaugh et al., *Proc. Natl. Acad. Sci USA* 91, 7071-7075 (1994). Other limitations include the inability to integrate into non-dividing cells (e.g., neurons, hepatocytes, myofibers, hematopoietic stem cells), modest vector titers available with current packaging systems, and the fragility of vector particles that precludes purification and concentration.

Lentiviruses are a subgroup of retroviruses that are capable of infecting non-dividing cells. L. Naldini et al. report a lentiviral vector system based on the human immunodeficiency virus (HIV) that is capable of transducing heterologous gene sequences into non-proliferative HeLa cells and rat fibroblasts, as well as into human primary macrophages and terminally differentiated neurons. *Science* 272, 263-267 (1996). However, the use of such a system in humans raises serious safety concerns, due to the possibility of recombination by the vector into a virulent and disease-causing form.

Accordingly, a need remains for a safe and efficient lentiviral vector systems capable of mediating gene transfer into a broad range of dividing and non-dividing cells.

#### SUMMARY OF THE INVENTION

The present invention is directed to the transfer of heterologous gene sequences into cells using Equine Infectious Anemia Virus (EIAV)-derived vectors for gene delivery.

A first aspect of the present invention is a recombinant lentiviral vector expression system including a first vector comprising a nucleic acid sequence of at least part of the Equine Infectious Anemia Virus (EIAV) genome, wherein the vector (i) contains at least one defect in at least one gene encoding an EIAV structural protein, and (ii) contains a defective packaging signal. The expression system additionally includes a second vector comprising a nucleic acid sequence of at least part of the EIAV genome, wherein the vector (i) contains a competent packaging signal, and (ii) contains a multiple cloning site wherein a heterologous gene may be inserted. The vector expression system also includes a third vector comprising a nucleic acid sequence of a virus, wherein the third vector (i) expresses a viral envelope protein, and (ii) contains a defective packaging signal.

A second aspect of the present invention is a method of producing a replication-defective lentivirus particle, comprising transfecting a cell with a vector expression system of the invention as described above.

A third aspect of the present invention is a method of delivering a heterologous gene to a target cell, comprising transfecting said target cell with a vector expression system of the invention as described above.

A fourth aspect of the present invention is a method of producing a lentiviral stock comprising (a) transfecting a producer cell with a vector expression system of the invention as described above; (b) growing the producer cell under cell culture conditions sufficient to allow production of replication-defective lentivirus particles in the cell; and (c) collecting the replication-defective lentivirus particles from the producer cell.

The foregoing and other aspects of the invention are explained in detail in the drawings herein and the specification set forth below.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic illustration of plasmid constructs used to generate EIAV-derived vectors of the present invention. Only a portion of each plasmid is depicted.

Figure 2A is a schematic illustration of the plasmid pEV53.

Figure 2B is a schematic illustration of the plasmid pEV53A.

Figure 3 is a schematic illustration of the plasmid pEC-lacZ.

Figure 4 is a schematic illustration of the plasmid pEC-puro.

Figure 5 is a schematic illustration of the plasmid pCI-VSV-G.

Figure 6A contains four photographs illustrating gene transfer to dividing  
5 (left column) and non-dividing (right-column) cells by MuLV (top row) and EIAV  
vectors (bottom row), as described in Example 3, below.

Figure 6B is a graphical representation of the comparative efficiency of gene  
transfer to dividing and non-dividing cells by MuLV-based vectors (left-hand pair of  
bar graphs) and EIAV-based vectors (right-hand pair of bar graphs). Successful  
10 gene transfer is represented on the y-axis of the graph as the percentage of infected  
cells that are stained blue (i.e., are X-gal positive), as described below.

Figure 6C is a graphical representation of the ability of aphidicolin to block  
the incorporation of bromodeoxyuridine (BrdU) into DNA in cells infected by  
MuLV-based gene transfer vectors. Successful gene transfer is represented on the y-  
15 axis of the graph as the percentage of infected cells that are positive for BrdU, as  
described in Example 3, below.

Figure 7 contains two graphs illustrating the ability of the EIAV-based  
vector EC-lacZ to infect and transfer genes dividing and non-dividing cells. In the  
left-hand graph of Figure 7, open circles represent human CFT1 cells not treated  
20 with aphidicolin, while closed circles represent human CFT1 cells treated with  
aphidicolin. In the right-hand graph of Figure 7, open triangles represent equine  
dermal cells not treated with aphidicolin, while closed triangles represent equine  
dermal cells treated with aphidicolin. In both graphs, gene transfer is represented on  
the y-axis as the percentage of infected cells that are X-gal positive. In both graphs,  
25 dosage of the EC-lacZ vector is represented on the x-axis in units of  $\mu\text{L}$  virus/mL  
inoculum.

Figure 8 is a dose-response curve of the infectivity of either unconcentrated  
(uncentrifuged) or concentrated (centrifuged) EC-lacZ/VSV-G pseudotyped virus  
particles. In Figure 8, open circles represent concentrated virus particles, while  
30 closed circles represent unconcentrated virus particles. Dosage of the EC-lacZ  
vector is represented on the x-axis in units of  $\mu\text{L}$  virus/mL inoculum, while  
infectivity is represented on the y-axis as percentage of cells positive for X-gal.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention now will be described more fully hereinafter with reference to the accompanying drawings, in which preferred embodiments of the invention are shown. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will fully convey the scope of the invention to those skilled in the art.

### I. The Equine Infectious Anemia Virus Genome

The Equine Infectious Anemia Virus (EIAV) is a member of the lentivirus genus of the retrovirus family. The wild type EIAV virus has a dimeric RNA genome (single-stranded, positive polarity) that is packaged into a spherical enveloped virion containing a nucleoprotein core. Replication of the wild type EIAV genome occurs via reverse transcription and integration into the host cell genome. The genome contains three genes that encode the structural proteins *gag*, *pol*, and *env*, and long terminal repeats (LTR) at each end of the integrated viral genome. In addition to the *gag*, *pol*, and *env* sequences common to all retroviruses, the EIAV genome contains several short open reading frames (ORFs). These short ORFs are translated from multiply spliced mRNAs. ORF S1 encodes the transcriptional transactivator *tat*. ORF S2 encodes a protein whose function is unknown, and the ORF S3 appears to encode a *rev* protein. It is thought that *rev* is required for the efficient expression of *gag*, *pol* and *env*. *Rev* acts post-transcriptionally by interacting with an RNA sequence known as the *rev*-responsive element (RRE), which is located in EIAV within the *env* gene.

The wild type genome of EIAV also contains several cis-acting sequences, including the R sequence (short repeat at each end of the genome); the U5 sequence (unique sequence element immediately after the R sequence); the U3 sequence (unique sequence element located downstream from the structural proteins); promoter elements that control transcriptional initiation of the integrated provirus; a packaging sequence (herein referred to interchangeably as a packaging site or a packaging signal); and a 5'-splice donor site.

## II. EIAV Vectors of the Present Invention

The vectors of the present invention provide a means for replicating and expressing heterologous nucleic acid independent of the host cell nucleus in a broad phylogenetic range of host cells. This vector-mediated incorporation of  
5 heterologous nucleic acid into a host cell is referred to as transfection or infection of the host cell, wherein infection means the use of virus particles, and transfection means the use of naked molecules of nucleic acid.

The vectors of the present invention additionally permit the incorporation of heterologous nucleic acid into virus particles, thereby providing a means for  
10 amplifying the number of infected host cells containing heterologous nucleic acid therein. The incorporation of the heterologous nucleic acid facilitates the replication of the heterologous nucleic acid within the viral particle, and the subsequent production of a heterologous protein therein. A heterologous protein is herein defined as a protein or fragment thereof wherein all or a portion of the protein is not  
15 expressed by the host cell. A nucleic acid or gene sequence is said to be heterologous if it is not naturally present in the wild type of the viral vector used to deliver the gene into a cell (e.g., the wild-type EIAV genome). The term nucleic acid sequence or gene sequence, as used herein, is intended to refer to a nucleic acid molecule (preferably DNA). Such gene sequences may be derived from a variety of  
20 sources including DNA, cDNA, synthetic DNA, RNA or combinations thereof. Such gene sequences may comprise genomic DNA which may or may not include naturally occurring introns. Moreover, such genomic DNA may be obtained in association with promoter sequences or poly-adenylation sequences. The gene sequences of the present invention are preferably cDNA. Genomic or cDNA may be  
25 obtained in any number of ways. Genomic DNA can be extracted and purified from suitable cells by means well-known in the art. Alternatively, mRNA can be isolated from a cell and used to prepare cDNA by reverse transcription, or other means.

It is an object of this invention to generate vectors capable of carrying out one single round of replication in the process of delivering a gene of interest to a  
30 target cell. An aspect of this technology is a gene delivery system that excludes the transfer of viral genes to the target cell. This is accomplished by physically separating expression vectors encoding viral genes from the vector encoding the



gene of interest. The separate expression vectors are transfected into a permissive cell (e.g., a "producing cell"). Viral gene products are necessary for the production of virus particles. However, in the present invention, genes coding for these genes are located on expression vectors that contain defective packaging signals;  
5 accordingly, the genes that code for the structural proteins are not packaged.

The phrases "structural protein" or "EIAV structural protein" as used herein refer to the encoded proteins which are required for encapsidation (e.g., packaging) of the EIAV genome, and include *gag*, *pol* and *env*.

The term "defective" as used herein refers to a nucleic acid sequence that is  
10 not functional with regard to either encoding its gene product or serving as a signaling sequence. To illustrate, a defective *env* gene sequence will not encode the *env* protein; a defective packaging signal will not facilitate the packaging of the nucleic acid molecule the defective signal is located on. Nucleic acid sequences may be made defective by any means known in the art, including by the deletion of  
15 some or all of the sequence, by placing the sequence out-of-frame, or by otherwise blocking the sequence.

As used herein, the terms "deleted" or "deletion" mean either total deletion of the specified segment or the deletion of a sufficient portion of the specified segment to render the segment inoperative or nonfunctional, in accordance with  
20 standard usage. The term "replication defective" as used herein, means that the vectors that encode EIAV structural proteins cannot be encapsidated in the target cell after transfection of the vectors. The resulting lentivirus particles are replication defective inasmuch as the packaged vector does not include all of the viral structural proteins required for encapsidation, at least one of the required structural proteins  
25 being deleted therefrom, such that the packaged vector is not capable of replicating the entire viral genome.

The preferred vectors of the present invention are derived from EIAV. Native EIAV nucleic acid may be isolated from cells infected with the virus, and vectors prepared therefrom. An exemplary method for preparing EIAV vectors is  
30 provided in S.T. Perry, et al., *J. Virol.* 66, 4085-4097 (1992). For example, cDNA may be produced from EIAV RNA by reverse transcriptase, using methods known in the art. Double-stranded EIAV cDNA may then be produced and cloned into a

cloning vector, such as a bacterial cloning vector. Any cloning vector, such as bacterial, yeast or eukaryotic vectors, known and used by those skilled in the art, may be used. The vectors of the present invention preferably comprise cDNA complementary to at least part of the RNA genome of EIAV. One vector may  
5 contain an heterologous cDNA molecule, which molecule can be introduced into human or animal cells to achieve transcription or expression of the heterologous molecule. The cDNA molecules will comprise cDNA complementary to at least part of a EIAV genome and comprising part of RNA genome required for replication of the genome, with the cDNA molecule being placed under transcriptional control  
10 of a promoter sequence functional in the cell.

A promoter sequence of the present invention may comprise a promoter of eukaryotic or prokaryotic origin, and will be sufficient to direct the transcription of a distally located sequence (i.e. a sequence linked to the 5' end of the promoter sequence) in a cell. The promoter region may also include control elements for the  
15 enhancement or repression of transcription. Suitable promoters are the cytomegalovirus immediate early promoter (pCMV), the Rous Sarcoma virus long terminal repeat promoter (pRSV), and the SP6, T3, or T7 promoters. Enhancer sequences upstream from the promoter or terminator sequences downstream of the coding region may be optionally be included in the vectors of the present invention  
20 to facilitate expression. Vectors of the present invention may also contain additional nucleic acid sequences, such as a polyadenylation sequence, a localization sequence, or a signal sequence, sufficient to permit a cell to efficiently and effectively process the protein expressed by the nucleic acid of the vector. Exemplified of preferred polyadenylation sequences are the SV40 early region polyadenylation site (C.V. Hall  
25 et al., *J. Molec. App. Genet.* 2, 101 (1983)) and the SV40 late region polyadenylation site (S. Carswell and J.C. Alwine, *Mol. Cell Biol.* 9, 4248 (1989)). Such additional sequences are inserted into the vector such that they are operably linked with the promoter sequence, if transcription is desired, or additionally with the initiation and processing sequence if translation and processing are desired. Alternatively, the  
30 inserted sequences may be placed at any position in the vector. The term "operably linked" is used to describe a linkage between a gene sequence and a promoter or other regulatory or processing sequence such that the transcription of the gene

sequence is directed by an operably linked promoter sequence, the translation of the gene sequence is directed by an operably linked translational regulatory sequence, and the post-translational processing of the gene sequence is directed by an operably linked processing sequence.

5           Standard techniques for the construction of the vectors of the present invention are well-known to those of ordinary skill in the art and can be found in such references as Sambrook et al., *Molecular Cloning: A Laboratory Manual 2nd Ed.* (Cold Spring Harbor, NY, 1989). A variety of strategies are available for ligating fragments of DNA, the choice of which depends on the nature of the termini  
10 of the DNA fragments and which choices can be readily made by the skilled artisan.

          In one embodiment of the present invention, a recombinant lentiviral expression system comprises three vectors. The first vector comprises a nucleic acid sequence of at least part of the Equine Infectious Anemia Virus (EIAV) genome, wherein the vector (i) contains at least one defect in at least one gene encoding an  
15 EIAV structural protein, and (ii) contains a defective packaging signal. The second vector comprises a nucleic acid sequence of at least part of the EIAV genome, wherein the vector (i) contains a competent packaging signal, and (ii) contains a multiple cloning site wherein a heterologous gene may be inserted. The third vector comprises a nucleic acid sequence of a virus, wherein the vector (i) expresses a viral  
20 envelope protein, and (ii) contains a defective packaging signal.

          In one embodiment of the invention, the first vector is a *gag/pol* expression vector. *Gag/pol* expression vectors express EIAV proteins required for assembly and release of viral particles from cells, and include the genes encoding proteins *gag* and *pol*. The first vector may also express genes encoding the accessory proteins *rev* and *tat*. The open reading frame S2, encoding a protein whose function is unknown,  
25 may additionally be included in the first vector. The first vector is constructed to contain mutations that exclude retroviral-mediated transfer of viral genes. Such mutations may be a deletion of sequences in the viral *env* gene, thus excluding the possibility of generating replication-competent EIAV, or may be deletions of certain  
30 cis-acting sequence elements at the 3' end of the genome required for viral reverse transcription and integration. Accordingly, even if viral genes from this construct are packaged into viral particles, they will not be replicated and replication-

competent wild-type viruses will not be generated.

In a preferred embodiment of the invention, the first vector of the expression system is the plasmid pEV53, shown in Figure 2A. pEV53 is a 12170 base-pair (bp) plasmid and cDNA clone which at base pairs 209-1072 contains a chimeric  
5 CMV/EIAV enhancer promoter region located upstream from the EIAV *tat* coding regions (bp 1124-1210 and 5886-6026), the *gag* coding region (bp 1216-2676), the *pol* coding region (bp 2433-5874) and the ORF S2 coding region (bp 6037-6234). The vector also contains a partial *env* coding region (bp 6063-7733) and *rev* coding regions (bp 6188-6288 and 7250-7654). The bovine growth hormone (BGH)  
10 polyadenylation signal is provided (bp 7759-7973), as is a phage *f1* region (bp 8037-8450), an SV40 early promoter region and origin of replication (bp 8514-8839), a neomycin resistance coding region (bp 9685-9924), a SV40 polyadenylation signal (bp 9685-9924), a Col E1 origin of replication (bp 10356-11029), and a  $\beta$ -lactamase (ampicillin resistance) coding region (bp 11174-12035).

15 In a more preferred embodiment of the present invention, the first vector of the expression system is the plasmid pEV53A, shown in Figure 2B. The plasmid pEV53A is derived from the pEV53 plasmid, wherein modifications have been made to further reduce the chances of retroviral-mediated transfer of viral genes without affecting the expression levels of EIAV proteins. In the plasmid pEV53A, all EIAV  
20 long terminal repeat (LTR) sequences containing promoter/enhancer elements and cis-acting sequence elements important for integration and the tRNA primer binding site sequence for initiation of reverse transcription has been deleted from pEV53. pEV53A is constructed from pEV53 by deleting nucleotides 902 through 1077 of pEV53.

25 The second vector of the expression system of the present invention is designed to serve as the vector for gene transfer, and contains all *cis*-acting sequence elements required to support reverse transcription (replication) of the vector genome, as well as a multiple cloning site for insertion of cDNAs encoding heterologous genes of interest. In the present invention, the vector encoding the gene of interest is  
30 a recombinant EIAV-derived vector that carries the genetic information to be transduced into a target cell, along with *cis*-acting sequence elements necessary for the packaging and integration of the viral genome. The second vector will

preferably contain some portion of the *gag* coding sequence, as it is believed that certain parts of the *gag* sequence play a role in the packaging of the EIAV genome. Moreover, the 5' splice donor site contained in the LTR will preferably contain a mutation that increases the titer of the produced virus, as described in, e.g., W. Tan et al., *J. Virol.* 70, 3645-3658 (1996).

Two examples of preferred second vectors are provided in Figures 3 and 4. Figure 3 illustrates the plasmid and cDNA clone pEC-lacZ, a 8749 bp plasmid derived from EIAV that expresses the *E. Coli* lacZ reporter gene. The plasmid contains two CMV immediate-early enhancer promoter regions (located at bp 1-734 and 1609-2224), R-U5 sequence domains from the EIAV long terminal repeat (LTR) (bp 735-849), a partial EIAV *gag* sequence (bp 993-1570), the lacZ coding sequence (bp 2297-5437), a EIAV LTR sequence (bp 5752-6073), a phage f1 region (bp 6163-6618), an ampicillin resistance coding region (bp 7057-7917) and a ColE1 origin of replication (bp 8062-8736).

Figure 4 illustrates the plasmid and cDNA clone pEC-puro, a 6099 bp plasmid derived from EIAV expressing the puromycin resistance gene. This vector also contains two CMV immediate-early enhancer promoter regions (bp 1-734 and 1609-2224), R-U5 sequence domains from the EIAV long terminal repeat (LTR) (bp 735-849), a partial gag sequence from EIAV (bp 993-1570), the puromycin resistance gene coding sequence (bp 2334-2933), an EIAV LTR sequence (bp 3102-3423), a phage f1 region (bp 3513-3968), an ampicillin resistance coding region (bp 4407-5267) and a ColE1 origin of DNA replication (bp 5412-6086).

As will be appreciated by one skilled in the art, the nucleotide sequence of the inserted heterologous gene sequence or sequences may be of any nucleotide sequence. For example, the inserted heterologous gene sequence may be a reporter gene sequence or a selectable marker gene sequence. A reporter gene sequence, as used herein, is any gene sequence which, when expressed, results in the production of a protein whose presence or activity can be monitored. Examples of suitable reporter genes include the gene for galactokinase, beta-galactosidase, chloramphenicol acetyltransferase, beta-lactamase, etc. Alternatively, the reporter gene sequence may be any gene sequence whose expression produces a gene product which affects cell physiology. Heterologous gene sequences of the present invention

may comprise one or more gene sequences that already possess one or more promoters, initiation sequences, or processing sequences.

A selectable marker gene sequence is any gene sequence capable of expressing a protein whose presence permits one to selectively propagate a cell which contains it. Examples of selectable marker genes include gene sequences  
5 capable of conferring host resistance to antibiotics (e.g., puromycin, ampicillin, tetracycline, kanamycin, and the like), or of conferring host resistance to amino acid analogues, or of permitting the growth of bacteria on additional carbon sources or under otherwise impermissible culture conditions. A gene sequence may be both a  
10 reporter gene and a selectable marker gene sequence. The most preferred reporter genes of the present invention are the lacZ gene which encodes the beta-galactosidase activity of *E. Coli*; and the gene encoding puromycin resistance.

Preferred reporter or selectable marker gene sequences are sufficient to permit the recognition or selection of the vector in normal cells. In one embodiment  
15 of the invention, the reporter gene sequence will encode an enzyme or other protein which is normally absent from mammalian cells, and whose presence can, therefore, definitively establish the presence of the vector in such a cell.

The heterologous gene sequence may also comprise the coding sequence of a desired product such as a suitable biologically active protein or polypeptide,  
20 immunogenic or antigenic protein or polypeptide, or a therapeutically active protein or polypeptide. Alternatively, the heterologous gene sequence may comprise a sequence complementary to an RNA sequence, such as an antisense RNA sequence, which antisense sequence can be administered to an individual to inhibit expression of a complementary polynucleotide in the cells of the individual.

25 Expression of the heterologous gene may provide immunogenic or antigenic protein or polypeptide to achieve an antibody response, which antibodies can be collected from an animal in a body fluid such as blood, serum or ascites.

In a preferred embodiment of the present invention, the third vector of the recombinant lentiviral expression system expresses a viral envelope protein. Such a  
30 vector will accordingly comprise a nucleic acid sequence encoding a viral protein under the control of a suitable promoter. It is possible to alter the host range of cells that the viral vectors of the present invention can infect by utilizing an envelope

gene from another closely related virus. In other words, it is possible to expand the host range of the EIAV vectors of the present invention by taking advantage of the capacity of the envelope proteins of certain viruses to participate in the encapsidation of other viruses. In a particularly preferred embodiment of the present invention, the G-protein of vesicular-stomatitis virus (VSV-G; *see, e.g.*, Rose and Gillione, *J. Virol.* 39, 519-528 (1981); Rose and Bergmann, *Cell* 30, 753-762 (1982)), or a fragment or derivative thereof, is the envelope protein expressed by the third vector. VSV-G efficiently forms pseudotyped virions with genome and matrix components of other viruses. As used herein, the term "pseudotype" refers to a viral particle that contains nucleic acid of one virus but the envelope protein of another virus. In general, VSV-G pseudotyped vectors have a very broad host range, and may be pelleted to titers of high concentration by ultracentrifugation (*e.g.*, according to the method of J. C. Burns, et al., *Proc. Natl. Acad. Sci. USA* 90, 8033-8037 (1993)), while still retaining high levels of infectivity.

An illustrative and preferred example of a third vector of the present invention is shown in Figure 5. This Figure illustrates the plasmid and cDNA clone pCI-VSV-G, a preferred expression vector for the envelope glycoprotein VSV-G. The plasmid contains 5679 base pairs and includes the CMV immediate-early enhancer promoter region (bp 1-795), a chimeric intron region (bp 857-989), the VSV-G coding region (bp 1088-2633), a phage fl region (3093-3548), a SV40 late polyadenylation signal (bp 2782-3003), a ColE1 origin of DNA replication (bp 4992-5666) and an ampicillin resistance coding region (bp 3987-4847).

In a method of the present invention, infectious, replication-defective EIAV particles may be prepared according to the methods disclosed herein in combination with techniques known to those skilled in the art. The method includes transfecting an lentivirus-permissive cell with the vector expression system of the present invention; producing the EIAV-derived particles in the transfected cell; and collecting the virus particles from the cell. The step of transfecting the lentivirus-permissive cell can be carried out according to any suitable means known to those skilled in the art. For example, in a method of the present invention, the three-plasmid expression system described herein is used to generate EIAV-derived retroviral vector particles by transient transfection. As another example, uptake of

the vectors into the cells can be achieved by any suitable means, such as for example, by treating the cells with DEAE-dextran, treating the RNA with "LIPOFECTIN<sup>®</sup>" before addition to the cells, or by electroporation. These techniques are well known in the art.

5       The step of facilitating the production of the infectious viral particles in the cells may also be carried out using conventional techniques, such as by standard cell culture growth techniques.

10       The step of collecting the infectious virus particles may also be carried out using conventional techniques. For example, the infectious particles may be collected by cell lysis, or collection of the supernatant of the cell culture, as is known in the art. Optionally, the collected virus particles may be purified if desired. Suitable purification techniques are well known to those skilled in the art.

15       If desired by the skilled artisan, lentiviral stock solutions may be prepared using the vectors and methods of the present invention. Methods of preparing viral stock solutions are known in the art and are illustrated by, e.g., Y. Soneoka et al., *Nucl. Acids Res.* 23, 628-633 (1995) and N.R. Landau et al., *J. Virol.* 66, 5110-5113 (1992). In a method of producing a stock solution in the present invention, lentiviral-permissive cells (referred to herein as producer cells) are transfected with the vector system of the present invention. The cells are then grown under suitable cell culture conditions, and the lentiviral particles collected from either the cells themselves or from the cell media as described above. Suitable producer cell lines include, but are not limited to, the human embryonic kidney cell line 293, the equine dermis cell line NBL-6, and the canine fetal thymus cell line Cf2TH.

20       The vectors of the present invention are also useful in preparing stable packaging cells (i.e. cells that stably express EIAV virus proteins, which cells, by themselves, cannot generate infectious virus particles). Methods for preparing packaging cells that express retrovirus proteins are known in the art and are exemplified by the methods set forth in, for example, U.S. Patent No. 4,650,764 to Temin et al., which disclosure is incorporated herein in its entirety. Within the scope of the present invention, a packaging cell will comprise a lentivirus-permissive host cell comprising an EIAV nucleic acid sequence coding for at least one EIAV structural protein, which nucleic acid sequence is packaging-signal



defective, thus rendering the cell itself capable of producing at least one EIAV structural protein, but not capable of producing replication-competent infectious virus. In one embodiment, the EIAV nucleic acid sequence is an EIAV *gag-pol* expression vector such as, for example, pEV53. A packaging cell may be made by  
5 transfecting an EIAV-permissive host cell (e.g., a human embryonic kidney 293 cell) with a suitable EIAV nucleic acid sequence as provided above according to known procedures. The resulting packaging cell is thus able to express and produce at least one EIAV structural protein. However, in that the EIAV nucleic acid sequence is defective in the packaging signal, the cell, on its own, is not able to produce  
10 replication-competent EIAV virus. The packaging cell may then be transfected with other nucleic acid sequences (e.g., pEC-puro, pEC-lacZ or pCI-VSV-G), which may contain heterologous genes of interest and an appropriate packaging signal. Once transfected with the additional sequence or sequences, the packaging cell may thus be used to provide stocks of EIAV viruses that contain heterologous genes, but  
15 which viruses are themselves replication-incompetent.

Pharmaceutical formulations, such as vaccines, of the present invention comprise an immunogenic amount of the infectious, replication defective virus particles as disclosed herein in combination with a pharmaceutically acceptable carrier. An "immunogenic amount" is an amount of the infectious virus particles  
20 which is sufficient to evoke an immune response in the subject to which the pharmaceutical formulation is administered. An amount of from about  $10^3$  to about  $10^7$  virus particles, and preferably about  $10^4$  to  $10^6$  virus particles per dose is believed suitable, depending upon the age and species of the subject being treated, and the immunogen against which the immune response is desired. Exemplary  
25 pharmaceutically acceptable carriers include, but are not limited to, sterile pyrogen-free water and sterile pyrogen-free physiological saline solution. Subjects which may be administered immunogenic amounts of the infectious, replication-defective virus particles of the present invention include but are not limited to human and animal (e.g., pig, cattle, dog, horse, donkey, mouse, hamster, monkeys) subjects.

30 Pharmaceutical formulations of the present invention include those suitable for parenteral (e.g., subcutaneous, intradermal, intramuscular, intravenous and intraarticular), oral or inhalation administration. Alternatively, pharmaceutical

formulations of the present invention may be suitable for administration to the mucus membranes of a subject (e.g., intranasal administration). The formulations may be conveniently prepared in unit dosage form and may be prepared by any of the methods well known in the art.

5           The vectors and methods of the present invention are useful in *in vitro* expression systems, wherein the inserted heterologous genes located on the second vector encode proteins or peptides which are desirably produced *in vitro*.

          The vectors, methods and pharmaceutical formulations of the present invention are additionally useful in a method of administering a protein or peptide to  
10 a subject in need of the desired protein or peptide, as a method of treatment or otherwise. In this embodiment of the invention, the heterologous gene located on the second vector of the present invention encodes the desired protein or peptide, and helper cells or pharmaceutical formulations containing the helper cells of the present invention are administered to a subject in need of the desired protein or  
15 peptide. In this manner, the protein or peptide may thus be produced *in vivo* in the subject. The subject may be in need of the protein or peptide because the subject has a deficiency of the protein or peptide, or because the production of the protein or peptide in the subject may impart some therapeutic effect, as a method of treatment or otherwise, and as explained further below.

### 20   III. Gene Transfer Technology

          The gene transfer technology of the present invention has several applications. The most immediate applications are perhaps in elucidating the process of peptides and functional domains of proteins. Cloned cDNA or genomic sequences for proteins can be introduced into different cell types in culture, or in  
25 vivo, in order to study cell-specific differences in processing and cellular fate. By placing the coding sequences under the control of a strong promoter, a substantial amount of the desired protein can be made. Furthermore, the specific residues involved in protein processing, intracellular sorting, or biological activity can be determined by mutational change in discrete residues of the coding sequences.

30           Gene transfer technology of the present invention can also be applied to provide a means to control expression of a protein and to assess its capacity to modulate cellular events. Some functions of proteins, such as their role in

differentiation, may be studied in tissue culture, whereas others will require reintroduction into *in vivo* systems at different times in development in order to monitor changes in relevant properties.

Gene transfer provides a means to study the nucleic acid sequences and cellular factors which regulate expression of specific genes. One approach to such a study would be to fuse the regulatory elements to be studied to reported genes and subsequently assaying the expression of the reporter gene.

Gene transfer also possesses substantial potential use in understanding and providing therapy for disease states. There are a number of inherited diseases in which defective genes are known and have been cloned. In some cases, the function of these cloned genes is known. In general, the above disease states fall into two classes: deficiency states, usually of enzymes, which are generally inherited in a recessive manner, and unbalanced states, at least sometimes involving regulatory or structural proteins, which are inherited in a dominant manner. For deficiency state diseases, gene transfer could be used to bring a normal gene into affected tissues for replacement therapy, as well as to create animal models for the disease using antisense mutations. For unbalanced disease states, gene transfer could be used to create a disease state in a model system, which could then be used in efforts to counteract the disease state. Thus the methods of the present invention permit the treatment of genetic diseases. As used herein, a disease state is treated by partially or wholly remedying the deficiency or imbalance which causes the disease or makes it more severe. The use of site-specific integration of nucleic sequences to cause mutations or to correct defects is also possible.

Hematopoietic stem cells, lymphocytes, vascular endothelial cells, respiratory epithelial cells, keratinocytes, skeletal and muscle cardiac cells, neurons and cancer cells are among proposed targets for therapeutic gene transfer, either *ex vivo* or *in vivo*. See, e.g., A.D. Miller, *Nature* 357, 455-460 (1992); R.C. Mulligan, *Science* 260, 926-932 (1993). These cells and others are suitable target cells for the vectors and methods of the present invention.

In summary, the viral vectors of the present invention can be used to stably transfect either dividing or non-dividing cells, and stably express a heterologous gene. Using this vector system, it is now possible to introduce into dividing or non-

dividing cells, genes which encode proteins that can affect the physiology of the cells. The vectors of the present invention can thus be useful in gene therapy for disease states, or for experimental modification of cell physiology.

Having now described the invention, the same will be illustrated with  
5 reference to certain examples which are included herein for the purposes of illustration only, and which are not intended to be limiting of the invention.

### Example 1 Plasmid Construction

10 The parent plasmid for EIAV vectors described herein is the plasmid pER2.1, generously provided by Dr. Fred Fuller of North Carolina State University, Raleigh, North Carolina, USA. The construction of the clone pER2.1 is described in S.T. Perry et al., *J. Virol.* 66, 4085-4097 (1992). pER2.1 encodes an infectious  
15 DNA clone of the Malmquist Wyoming strain of EIAV. One safety aspect of this clone is that the virus generated does not cause disease in its natural equine host. Also, unlike vectors derived from other retroviruses (e.g., murine leukemia virus, human immunodeficiency virus) considered for use in gene transfer, wild type EIAV does not mount an active infection in human cells.

20 EIAV gag/pol (first) expression vector. The pEV53 plasmid (shown in Figure 2A) was designed to express EIAV proteins required for assembly and release of viral particles from cells, and includes genes encoding proteins encoded by the *gag* and *pol* genes, and the accessory proteins *rev* and *tat*. The open reading frame S2, encoding a protein whose function is not known, was also included.  
25 pEV53 was constructed to contain mutations that exclude retroviral-mediated transfer of viral genes. The mutations include sequence deletions in the viral *env* gene (thus excluding the possibility of generating replication-competent EIAV virus particles) and deletion of certain *cis*-acting sequence elements at the 3' end of the genome required for viral reverse transcription and integration. Deletions are  
30 included such that in the unlikely event that viral genes are packaged into the infectious particles, they will not be replicated (e.g., replication-competent wild-type vectors will not be generated). The plasmid pEV53A, shown in Figure 2B, is derived from pEV53, but differs from pEV53 in that all EIAV long terminal repeat

(LTR) sequences containing promoter/enhancer elements and cis-acting sequence elements important for integration, as well as the tRNA primer binding site sequence for initiation of reverse transcription, have been deleted by removing nucleotides 902 through 1077 from pEV53). The pEV53A plasmid was made to further reduce the chances of retroviral-mediated transfer of viral genes without affecting the expression levels of EIAV proteins

**Gene Transfer (second) vector.** The pEC-lacZ (shown in Figure 3) and pEC-puro (shown in Figure 4) plasmids were designed to serve as the vector for gene transfer and contain all cis-acting sequence elements required to support reverse transcription (e.g., replication) of the vector genome, as well as a multiple cloning site for insertion of cDNAs encoding genes of interest. The pEC-lacZ plasmid encodes the beta-galactosidase reporter gene *lacZ*, while the pEC-puro plasmid encodes the puromycin-N-acetyl transferase dominant selectable marker gene *puro*.

**Viral envelope gene expression (third) vector.** The third plasmid of the expression system described herein is the plasmid pCI-VSV-G, shown in Figure 5. This plasmid expresses a viral envelope gene, specifically the vesicular stomatitis virus G glycoprotein gene.

## **Example 2**

### **Production and Testing of Viral Vectors**

EIAV vectors were produced following standard calcium phosphate-mediated co-transfection of the pEV53A gag-pol expression plasmid, the pCI-VSV-G env expression plasmid, and either the pEC-lacZ or pEC-puro expression vector plasmids into cultures of human 293 cells (American Type Culture Collection, Rockville, MD). 48 hours after transfection, the culture medium was harvested from the cells and tested for EIAV vector production. The gene transfer efficiency of the pEC-puro vector was measured by the ability of serial dilutions of the vector to confer resistance to the drug puromycin. In this assay, an infected cell gives rise to a drug-resistant colony of cells, which can then be counted. Human 293 cells were used as the target cells. From six independent experiments, the average titer of the EC-puro vector was determined to be  $2 \pm 1 \times 10^5$  colony forming units (cfu) per mL.

The gene transfer efficiency of the EC-lacZ vector was determined by staining infected human CFT1 human airway epithelial cells with X-gal (Molecular Probes, Inc., Eugene, Oregon), an analog of galactose. In this assay, cells expressing the beta-galactosidase gene will turn blue, and the percentage of blue cells is  
5 determined by counting. The titer of virus by multiplying the fraction of stained cells by the number of cells initially infected. In this manner, the titer of the EC-lacZ virus was determined to be about  $5 \pm 1 \times 10^4$  infectious units (n=5) per mL.

Several control experiments were performed to determine whether the expression of the puro and lacZ genes were indeed mediated by viral components.  
10 In the first experiment, it was shown for both the EC-puro and EC-lacZ vectors that both the pEV53 or pEV53A and the pCI-VSV-G vectors were essential for gene transfer. The result is consistent with gene transfer and expression mediated by virus (and not free DNA). In a second control experiment using the lacZ vector, cells were stained with X-gal immediately after a two-hour infection and no blue  
15 cells were found. The result is consistent with temporal aspects of reverse transcription, integration and gene expression, which for other retroviruses are known to require a minimum of about 10 hours to complete.

### Example 3 Gene Transfer to Non-Dividing Cells

20 EIAV is capable of infecting non-dividing, terminally differentiated cells, such as macrophages and airway epithelia. To test this property with the present invention, human CFT1 airway epithelial cells (generously provided by J.R. Yankaskas of the University of North Carolina at Chapel Hill) were arrested in the  
25 cell cycle with aphidicolin (Calbiochem-Novabiochem Corp., La Jolla, California), and then infected with the pEC-lacZ vector. As a control, cells were infected in parallel with the LZ vector, a lacZ-containing retrovirus vector derived from the murine leukemia virus (MuLV). 48 hours after infection, cultures were stained for  
30 beta-galactosidase activity with X-gal. In the aphidicolin treated cultures, aphidicolin was present both during and after infection.

Microscopic fields of the stained cells are shown in Figure 6A. The LZ vector efficiently infected cells not treated with aphidicolin (upper left panel). However, when cells were arrested in the cell cycle by aphidicolin treatment, gene

transfer efficiency dropped markedly (upper right panel). It was estimated by counting the rare blue-stained cell that the relative efficiency of gene transfer to dividing cells to non-dividing cells was about 100 to 1 for the LZ vector (as shown in Figure 6B, left-hand pair of bar graphs). The results are consistent with results  
5 obtained in experiments in other laboratories. *See e.g.*, D.G. Miller et al., *Mol. Cell. Biol.* 10, 4329-4242 (1990); P.F. Lewis and M. Emerman, *J. Virol.*, 68, 510-516 (1994). At the time of infection, parallel cultures were pulsed with bromodeoxyuridine (BrdU) for 2 hours to test the efficacy of the aphidicolin block and analyzed for BrdU incorporation into DNA, as shown in Figure 6C. It was  
10 found that aphidicolin markedly reduced the incorporation of BrdU into DNA.

In contrast to the results obtained with the LZ vector, aphidicolin treatment had no significant effect on the percentage of human CFT1 cells infected by the EC-lacZ vector (see results in Figures 6A, lower panels, and 6B, right-hand pair of bar graphs). These results indicate that EIAV vectors can efficiently infect non-  
15 dividing cells. For example, in the experiment shown in Figure 7, the equine dermal fibroblast cell line NBL-6 was infected about 10 times more readily (for a given amount of virus), when cells were treated with aphidicolin, as compared to cells that were not treated with aphidicolin.

20

#### Example 4

##### Ultracentrifugation of VSV-G Pseudotyped EIAV Vectors

One advantage of VSV-G pseudotyped vectors is that the increased stability afforded by VSV-G permits concentration of infectivity by pelleting in an  
25 ultracentrifuge (*see, e.g.*, J. C. Burns, et al., *Proc. Natl. Acad. Sci. USA* 90, 8033-8037 (1993)). It was determined that infectivity of VSV-G pseudotyped EIAV vectors can also be recovered by pelleting using centrifugation techniques. In this experiment, 720 ml of EC-lacZ-containing supernatant from a 2-plasmid (pEC-lacZ/pCI-VSV-G) co-transfection of 293 cells (stably modified to express the  
30 pEV53 plasmid) was concentrated by pelleting the virus in a high-speed centrifuge. The pellet was suspended in 0.36 ml of 1X Hank's Balanced Salt Solution (HBSS, Cat. # 14175, Life Technologies, Inc., Gaithersburg, MD) to achieve a 2000-fold concentration of virus particles. The infectivity was determined (see Figure 8 for a

dose-response curve of infectivity) and it was found that the titer increased about 1200-fold from  $5 \times 10^5$  to  $6 \times 10^8$ . Thus, the yield of infectivity was about 60%. This result illustrates that EIAV vectors can be concentrated to high titers by pelleting.

5  
**Example 5**  
**Packaging Cell Line**

For stable packaging cells, the human embryonic kidney cell line 293 was transfected using a standard calcium transfection procedure with pEV53. The cells  
10 were selected for expression of neomycin using G418 (geneticin) (Life Technologies Inc., Gaithersburg Maryland, USA). Individual colonies were selected, expanded and tested for virus production after transfecting with pECpuro and pCI-VSV-G. Clonal packaging cell lines showing the greatest vector production were either  
15 frozen for long-term storage or were maintained in culture for analysis of persistence of packaging function. It was found that the packaging function was stable for at least one month, indicating that the present invention is useful and successful in the preparation of stable, EIAV-based packaging cell lines.

While the invention has been described in connection with specific  
embodiments thereof, it will be understood that the invention is capable of further  
20 modification and this application is intended to cover any variations, uses or adaptations of invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains, and as may be applied to the essential features set forth in the scope of the appended claims.



**THAT WHICH IS CLAIMED:**

1. A recombinant lentiviral vector expression system comprising:
  - (a) a first vector comprising a nucleic acid sequence of at least part of the Equine Infectious Anemia Virus (EIAV) genome, wherein said vector (i) contains at least one defect in at least one gene encoding an EIAV structural protein, and (ii) contains a defective packaging signal;
  - (b) a second vector comprising a nucleic acid sequence of at least part of the EIAV genome, wherein said vector (i) contains a competent packaging signal, and (ii) contains a multiple cloning site wherein a heterologous gene may be inserted;
  - and
  - (c) a third vector comprising a nucleic acid sequence of a virus, wherein said third vector (i) expresses a viral envelope protein, and (ii) contains a defective packaging signal.
2. A vector system according to Claim 1, wherein said second vector is deficient for expression of at least one EIAV structural protein.
3. A vector system according to Claim 1, wherein said first vector, said second vector, and said third vector are cDNA clones of at least part of the EIAV genome.
4. A vector expression system according to Claim 1, wherein said first vector is a *gag-pol* expression vector, and wherein said vector contains a defect in the *env* gene.
5. A vector expression system according to Claim 4, wherein said defect in the *env* gene is a deletion mutation.
6. A vector expression system according to Claim 1, wherein said first vector and said second vector each contain a defect in the *env* gene.
7. A vector expression system according to Claim 1, wherein said third

vector encodes an envelope protein that is not an EIAV envelope protein.

8. A vector expression system according to Claim 1, wherein said third vector expresses the vesicular stomatitis virus G glycoprotein.

5

9. A vector expression system according to Claim 1, wherein said second vector contains a heterologous gene.

10. A vector expression system according to Claim 9, wherein said heterologous gene encodes an antigenic protein or peptide.

10

11. A vector expression system according to Claim 1, wherein said first vector is selected from the group consisting of the plasmid pEV53 and the plasmid pEV53A; said second vector is selected from the group consisting of pEC-lacZ and pEC-puro; and said third vector is the plasmid pCI-VSV-G.

15

12. The plasmid set forth in FIG.2A as pEV53.

13. The plasmid set forth in FIG.2B as pEV53A.

20

14. The plasmid set forth in FIG. 2 as pEC lacZ.

15. The plasmid set forth in FIG. 3 as pEC-puro.

25

16. The plasmid set forth in FIG.4 as pCI-VSV-G.

17. A method of producing a replication-defective lentivirus particle, comprising transfecting a cell with:

(a) a first vector comprising a nucleic acid sequence of at least part of the Equine Infectious Anemia Virus (EIAV) genome, wherein said vector (i) contains at least one defect in at least one gene encoding an EIAV structural protein, and (ii) contains a defective packaging signal;

30

(b) a second vector comprising a nucleic acid sequence of at least part of the EIAV genome, wherein said vector (i) contains a competent packaging signal, and (ii) contains a multiple cloning site wherein a heterologous gene may be inserted; and

5 (c) a third vector comprising a nucleic acid sequence of a virus, wherein said third vector (i) expresses a viral envelope protein, and (ii) contains a defective packaging signal.

10 18. A method according to Claim 17, wherein said cell is a non-dividing cell.

19. A method according to Claim 17, wherein said second vector contains a heterologous gene.

15 20. A replication-defective lentivirus particle produced according to the method of Claim 17.

20 21. An infectious EIAV particle containing an EIAV nucleic acid sequence encoding a promoter and a heterologous gene sequence, and wherein said nucleic acid sequence is defective in encoding at least one EIAV structural protein so that said virus particle is replication defective.

22. A cell containing a replication-defective lentiviral particle, wherein said lentiviral particle is produced according to the method of Claim 17.

25 23. A method of delivering a heterologous gene to a target cell, comprising transfecting said target cell with:

30 (a) a first vector comprising a nucleic acid sequence of at least part of the Equine Infectious Anemia Virus (EIAV) genome, wherein said vector (i) contains at least one defect in at least one gene encoding an EIAV structural protein, and (ii) contains a defective packaging signal;

(b) a second vector comprising a nucleic acid sequence of at least part of the

EIAV genome, wherein said vector (i) contains a competent packaging signal, and (ii) contains a multiple cloning site wherein a heterologous gene may be inserted; and

- (c) a third vector comprising a nucleic acid sequence of a virus, wherein said third vector (i) expresses a viral envelope protein, and (ii) contains a defective packaging signal.

24. A method according to Claim 23, wherein said target cell is a non-dividing cell.

25. A method of producing a lentiviral stock comprising:

- (a) transfecting a lentivirus-permissive producer cell with
- (i) a first vector comprising a nucleic acid sequence of at least part of the Equine Infectious Anemia Virus (EIAV) genome, wherein said vector (1) contains at least one defect in at least one gene encoding an EIAV structural protein, and (2) contains a defective packaging signal;
- (ii) a second vector comprising a nucleic acid sequence of at least part of the EIAV genome, wherein said vector (1) contains a competent packaging signal, (2) contains a heterologous gene; and
- (iii) a third vector comprising a nucleic acid sequence of a virus, wherein said third vector (1) expresses a viral envelope protein, and (2) contains a defective packaging signal;
- (b) growing said producer cell under cell culture conditions sufficient to allow production of replication-defective lentivirus particles in said cell; and
- (c) collecting said replication-defective lentivirus particles from said producer cell.

26. A method according to Claim 25, wherein said producer cell is grown in a cell culture medium, and wherein said replication-defective lentivirus particles are collected from said medium.

27. A method of delivering a heterologous gene to a target cell, comprising infecting said target cell with replication-defective lentivirus particles collected according to step (c) of Claim 25.

28. A method according to Claim 27, wherein said target cell is a non-dividing cell.

29. A method according to Claim 27, wherein said target cell is a human  
5 airway epithelial cell.

30. A method of delivering a heterologous gene to a target cell, comprising infecting said target cell with a replication-defective lentivirus particle according to Claim 20 or 21.

10

31. A pharmaceutical formulation comprising a replication-defective lentivirus particle according to Claim 20 or Claim 21 in a pharmaceutically acceptable carrier.

15

32. A method of making a packaging cell, comprising transfecting a lentivirus-permissive cell with a vector comprising a nucleic acid sequence of at least part of the Equine Infectious Anemia Virus (EIAV) genome, wherein said vector contains a defective packaging signal.

20

33. A method according to Claim 32, wherein said vector is a gal-pol expression vector.

34. A method according to Claim 32, wherein said vector is selected from the group consisting of the plasmid pEV53 and the plasmid pEV53A.

25

35. A method according to Claim 32, wherein said lentivirus-permissive cell is a human 293 cell.

30

36. A packaging cell comprising a lentivirus-permissive host cell containing an EIAV nucleic acid sequence encoding at least one EIAV structural protein, wherein said nucleic acid sequence is packaging-signal defective, such that the cell itself is capable of producing at least one EIAV structural protein, but not capable of producing replication-competent infectious virus.

FIG. 1A

EIAV  
(pER2.1)






FIG. 1B

EIAV gag/pol  
expression  
vector  
(pEV53)



EIAV vectors:

FIG. 1C



pEC-puro




FIG. 1D

viral envelope  
gene expression  
vector





FIG. 1E


2/11

FIG. 2A



3/11


FIG. 2B






4/11

FIG. 3




5/11

FIG. 4



6/11

FIG. 5



7/11




FIG.6A

8/11

FIG. 6C






FIG. 6B




9/11

FIG. 7A




10/11

FIG. 7B



11/11

FIG. 8





# INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/US 98/10144

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/86 C12N7/01 C12N7/04 C07K14/145 C07K14/16  
A61K48/00 A61K39/21

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 12622 A (SALK INST FOR BIOLOGICAL STUDY) 10 April 1997 see page 1 - page 2 see page 5, line 13 - page 7, line 25 see figure 1	16
Y		1-15, 17-28, 30-36 29
A		
X	NALDINI L ET AL: "IN VIVO GENE DELIVERY AND STABLE TRANSDUCTION OF NONDIVIDING CELLS BY A LENTIVIRAL VECTOR" SCIENCE, vol. 272, no. 5259, 12 April 1996, pages 263-267, XP000583652 cited in the application see the whole document	16

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

15 September 1998

Date of mailing of the international search report

25/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 851 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Galli, I

# INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/US 98/10144

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ORY D S ET AL: "A STABLE HUMAN-DERIVED PACKAGING CELL LINE FOR PRODUCTION OF HIGH TITER RETROVIRUS/VESICULAR STOMATITIS VIRUS G PSEUDOTYPES"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,</p> <p>vol. 93, October 1996, pages 11400-11406, XP002030784</p> <p>see page 11401, column 1; figure 1</p>	16
Y	<p>PERRY S.T. ET AL.: "The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro"</p> <p>J. VIROL.,</p> <p>vol. 66, no. 7, July 1992, pages 4085-4097, XP002077536</p> <p>cited in the application</p> <p>see the whole document</p>	1-15, 17-28, 30-36
A	<p>WEISS R.A.: "Retrovirus classification and cell interactions"</p> <p>J. ANTIMICROB. CHEMOTHERAPY,</p> <p>vol. 37, no. Suppl. B, 1996, pages 1-11, XP002077537</p> <p>see abstract</p> <p>see tables 2,5</p>	1-36
A	<p>MAURY W.J. ET AL.: "Cellular and viral specificity of Equine Infectious Anemia Virus Tat protein"</p> <p>VIROLOGY,</p> <p>vol. 200, no. 2, 1994, pages 632-642, XP002077562</p> <p>see abstract</p> <p>see page 636</p>	1-36
P,X	<p>WO 98 17815 A (KINGSMAN SUSAN MARY ;MITROPHANOUS KYRIACOS (GB); OXFORD BIOMEDICA) 30 April 1998</p> <p>see abstract</p> <p>see page 5, line 13 - line 26</p>	1-36
T	<p>ZUFFEREY R ET AL: "MULTIPLY ATTENUATED LENTIVIRAL VECTOR ACHIEVES EFFICIENT GENE DELIVERY IN VIVO"</p> <p>NATURE BIOTECHNOLOGY,</p> <p>vol. 15, September 1997, pages 871-875, XP002056816</p> <p>see page 871</p>	1-36

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/10144

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Please see Further Information Sheet enclosed.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Remark: Although claims 27-30, as far as methods in vivo are concerned, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/10144

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9712622 A	10-04-1997	AU 7168196 A	28-04-1997
WO 9817815 A	30-04-1998	AU 4712297 A	15-05-1998
		AU 4712397 A	15-05-1998
		WO 9817816 A	30-04-1998